Abstract 2848
Background
Lysosome has been described as target of interest for cancer therapy. GNS561 is a new lysosomotropic small molecule which displays meaningful activity against several tumor types, specifically in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Herein, we report preliminary results of the Phase 1b/2a study of GNS561 in advanced primary liver cancer patients.
Methods
The Phase 1b portion is a non-randomized, one arm (3 + 3 design) clinical trial with a maximum enrolment of 36 patients. GNS561 was administered orally to histologically confirmed HCC or iCCA adult patients not eligible for curative therapy in 4 week cycles. The objectives are to assess the safety and pharmacokinetics (PK) of GNS561 and to determine the recommended phase 2 dose. Early safety, PD and PK data from patients of the 4 first dose levels are reported.
Results
As of May 2019, 13 patients were enrolled with 10 patients having completed the study with at least one cycle of treatment. Median patient age was 66 years (range 31 - 80), 3 (23%) were female, 6 (46%) had HCC; median number of prior systemic therapies was 1 (range 1-5). Patients received a median number of 2 cycles of GNS561. Six (46%) patients interrupted treatment because of tumor progression, 31% (n = 4) for investigator decision, and 7.7% (n = 1) for serious adverse event. Thus far, no dose limiting toxicity (DLT), or DLT equivalent toxicity have been observed. Most of related-AEs are digestive toxicities (grade 1-2 nausea, vomiting and diarrhea), fatigue and blood parameters abnormalities. The 400 mg cohort is currently ongoing. 70% (n = 7) patients were evaluable for tumor imaging assessment: 43% of them (n = 3) were stable at the beginning of Cycle 3, among which 2 patients had stable disease at the beginning of Cycle 5. Patients showed increasing exposure to GNS561 along with the dose in blood and liver, with dose-proportionality in plasma. Liver concentrations are at least 200 fold higher than in plasma.
Conclusions
Current data show patients that oral GNS561 displays a favorable safety profile, and exposure in blood and liver throughout the dosing interval. Enrollment in Phase 1b is continuing before extension to Phase 2a.
Clinical trial identification
2017-003585-27.
Editorial acknowledgement
Legal entity responsible for the study
Genoscience Pharma.
Funding
Genoscience Pharma.
Disclosure
A.H. Awada: Honoraria (institution), Advisory / Consultancy: Genoscience Pharma. J.J. Harding: Honoraria (institution), Advisory / Consultancy: Genoscience Pharma. N. Kotecki: Honoraria (institution): Genoscience Pharma. P.G. Aftimos: Honoraria (institution): Genoscience Pharma. T. Decaens: Honoraria (institution): Genoscience Pharma. C. Dreyer: Honoraria (institution): Genoscience Pharma. C. Ansaldi: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genoscience Pharma. M. Rachid: Full / Part-time employment: Genoscience Pharma. C. Serdjebi: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genoscience Pharma. P. Halfon: Leadership role, Shareholder / Stockholder / Stock options, Officer / Board of Directors: Genoscience Pharma. G.K. Abou-Alfa: Honoraria (institution), Advisory / Consultancy: Genoscience Pharma. E. Raymond: Advisory / Consultancy, Shareholder / Stockholder / Stock options, Full / Part-time employment: Genoscience Pharma.
Resources from the same session
1902 - Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Jae Ho Jeong
Session: Poster Display session 2
Resources:
Abstract
3716 - Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma
Presenter: Naru Kim
Session: Poster Display session 2
Resources:
Abstract
3947 - Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
Presenter: Teresa Macarulla
Session: Poster Display session 2
Resources:
Abstract
2880 - Expression of long noncoding RNA and clinical outcomes of pancreatic cancer patients who received adjuvant chemotherapy by S-1 or GEM after curative resection.
Presenter: Mariko Kamiya
Session: Poster Display session 2
Resources:
Abstract
5029 - POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Presenter: Eric Van Cutsem
Session: Poster Display session 2
Resources:
Abstract
4730 - Diagnostic Value of Digital Multiplexed Detection of Single Nucleotide Variants in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasound Fine-Needle Aspiration
Presenter: Irina Cazacu
Session: Poster Display session 2
Resources:
Abstract
3303 - Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Presenter: Esther Pijnappel
Session: Poster Display session 2
Resources:
Abstract
2009 - Efficacy of platinum-containing chemotherapy and prognosis of pancreatic cancer patients with homologous recombination deficiency: meta-analysis of published clinical studies
Presenter: Elizeveta Polyanskaya
Session: Poster Display session 2
Resources:
Abstract
2164 - Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
Presenter: Valeria Merz
Session: Poster Display session 2
Resources:
Abstract
2529 - A protein level signature of four selected genes associated with survival outcomes of patients with pancreatic ductal adenocarcinoma
Presenter: Jie Hua
Session: Poster Display session 2
Resources:
Abstract